<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00900614</url>
  </required_header>
  <id_info>
    <org_study_id>APR-246-01</org_study_id>
    <nct_id>NCT00900614</nct_id>
  </id_info>
  <brief_title>Safety Study of APR-246 in Patients With Refractory Hematologic Cancer or Prostate Cancer</brief_title>
  <official_title>An Open-label Phase I Dose Escalating Study of APR-246 for Infusion in Patients With Refractory Hematologic Malignancies or Prostate Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aprea Therapeutics AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aprea Therapeutics AB</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the highest feasible dose (HFD) of intravenous (IV)
      APR-246 when given to patients with refractory hematologic malignancies or prostate
      carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-Limiting Toxicity (DLT) is reached and HFD is defined accordingly, OR the dose, which is expected to result in maximum plasma concentration close to, but not exceeding 35 μg/ml in any single patient without showing signs of DLT.</measure>
    <time_frame>21 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determination of the toxicity and safety profile of APR-246 based on safety parameters from the entire study period.</measure>
    <time_frame>continuously during 21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of the PK profile for up to 22 hours after the last APR-246 infusion. Cmax (maximal plasma concentration), AUC (area under the curve), t1/2 (half-life) and clearance will be determined.</measure>
    <time_frame>continuously, during 21 days</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Hematologic Neoplasms</condition>
  <condition>Prostatic Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APR-246</intervention_name>
    <description>Intravenous infusion. Dose escalating. Dosing will be conducted with three patients at each dose level.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Summary criteria for participant selection:

        Inclusion Criteria:

          -  Male or female ≥ 18 years of age.

          -  Any below mentioned advanced disease, which is not eligible for other therapies. The
             diagnosis should have been confirmed either histologically or cytologically:

               1. Acute myeloid leukemia.

               2. Acute lymphoid leukemia.

               3. Chronic lymphocytic leukemia.

               4. Chronic myeloid leukemia.

               5. Chronic myelomonocytic leukemia.

               6. Multiple myeloma.

               7. Non Hodgkin's lymphoma.

               8. Hodgkin's lymphoma.

               9. Myelodysplastic syndrome.

              10. Myelofibrosis.

              11. Hormone refractory, metastatic prostate carcinoma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sören Lehmann, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hematology Centre, M54, Karolinska Institute, Karolinska University Hospital, Huddinge, SE-141 86, Stockholm, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Section of Haematology and Coagulation, Sahlgrenska University Hospital</name>
      <address>
        <city>Göteborg</city>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Centre, M54, Karolinska Institute, Karolinska University Hospital, Huddinge</name>
      <address>
        <city>Stockholm</city>
        <zip>SE 141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research and Development Unit, Department of Oncology, Akademiska Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Haematology, Akademiska Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Hematology, University Hospital</name>
      <address>
        <city>Örebro</city>
        <zip>70185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology clinic, University Hospital</name>
      <address>
        <city>Örebro</city>
        <zip>70185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2009</study_first_submitted>
  <study_first_submitted_qc>May 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2009</study_first_posted>
  <last_update_submitted>June 22, 2011</last_update_submitted>
  <last_update_submitted_qc>June 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2011</last_update_posted>
  <responsible_party>
    <name_title>Charlotta Liljebris</name_title>
    <organization>Aprea AB</organization>
  </responsible_party>
  <keyword>Hematologic malignancy</keyword>
  <keyword>Prostate carcinoma</keyword>
  <keyword>Hematologic cancer</keyword>
  <keyword>Prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

